Reviewer’s report

Title: Prevention of allergic airway hyperresponsiveness and remodeling in mice by Astragaliradix Antiasthmatic decoction

Version: 3 Date: 6 September 2013

Reviewer: Rekha R. Shenoy

Reviewer’s report:

1. In figures 5A, 5C and 5D, the spikes [for SEM] on the bar graphs are not clear as shown in figure 5B
2. The dose of the drug is very high… 7.5 g or 15 g?? How did the authors fix the dose? Was any Acute Oral Toxicity done according to OECD guidelines or ICH guidelines?
3. The acute or chronic toxicities have not been done.
4. How safe is Astragali? Were any side effects noted?
5. The histo-pathological images are not clear in Figures 3A and 4A. Arrows could have been inserted in the images to clearly state the pathology as described in the figure legends.

Minor revisions
1. In abstract, the spelling of hyper-responsiveness is wrong. Even in abbreviation, it is wrong
2. In results, spelling of collagen is wrong
3. Under background section, spelling of dried is wrong, many typing errors are there in the article
4. Methacholine is abbreviated as Mech, at some places Mch.. Keep the abbreviation uniform
5. Figure 1 spelling of Methacholine is wrong

Discretionary revisions
1. The influence of traditional Chinese Medicine Astragali-Cordyceps Mixtura (ACM) on TGF-#/Smad signal pathway in the lung of asthma airway remodeling has already been established earlier. What is novel in this work?
2. The discussion has been poorly written.
3. Why did the authors not use albino or Sprague Dawley rat models to assess hyper responsiveness?

Level of interest: An article whose findings are important to those with closely related research interests
Quality of written English: Needs some language corrections before being published

Statistical review: Yes, and I have assessed the statistics in my report.

Declaration of competing interests:
I declare that I have no competing interests